文献速递乳腺癌支持与姑息治疗

MBL2与CD95基因多态性与多柔比星联合环磷酰胺辅助治疗乳腺癌后3级感染的药物遗传学关联

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.
PubMed 文献 · Eur J Cancer · 2016-12-08

研究探讨CD95启动子单核苷酸多态性(rs2234767)与MBL2启动子单核苷酸多态性(rs7096206)同乳腺癌患者接受多柔比星联合环磷酰胺化疗后发生3级感染的关联。CD95次要等位基因纯合子较杂合子及野生型纯合子更易发生3级感染(29%、3%、5%,p=0.048)。MBL2单核苷酸多态性与3级感染呈等位基因剂量关联(野生型纯合子2%、杂合子8%、次要等位基因纯合子17%,p=0.02)。

要点

  • CD95次要等位基因纯合子3级感染发生率为29%,杂合子3%,野生型纯合子5%(p=0.048)。
  • MBL2野生型纯合子、杂合子、次要等位基因纯合子的3级感染率分别为2%、8%、17%(p=0.02)。
  • CD95次要等位基因纯合子基线白细胞与中性粒细胞计数高于野生型等位基因携带者,且贯穿治疗全程。

核心结论

  • CD95与MBL2单核苷酸多态性与乳腺癌多柔比星联合环磷酰胺化疗后3级感染存在关联,提示药物遗传学方法或有助于识别化疗期间易发生威胁生命感染的患者。
  • CD95单核苷酸多态性与轻度中性粒细胞增多之间的表观关联值得进一步研究。

研究设计与样本

  • 研究探讨免疫功能相关两个基因的单核苷酸多态性,以识别乳腺癌多柔比星联合环磷酰胺治疗后严重感染的关联。

主要发现

  • CD95次要等位基因纯合子较杂合子与野生型纯合子更易发生3级感染(29%、3%和5%,p=0.048)。
  • CD95次要等位基因纯合子基线白细胞和中性粒细胞计数高于野生型等位基因携带者,且贯穿治疗全程。
  • MBL2单核苷酸多态性与3级感染呈等位基因剂量关联:野生型纯合子2%、杂合子8%、次要等位基因纯合子17%发生3级感染(p=0.02)。

关键数值与推荐

  • CD95次要等位基因纯合子3级感染发生率29%,杂合子3%,野生型纯合子5%(p=0.048)。
  • MBL2野生型纯合子3级感染发生率2%,杂合子8%,次要等位基因纯合子17%(p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Life-threatening infection as an adverse reaction to cytotoxic therapy of cancer remains a major problem, potentially limiting efficacy. Administration of colony-stimulation factors benefits only a minority of patients, and improved stratification guidelines are needed to identify those patients likely to benefit. We investigated single nucleotide polymorphisms (SNPs) in two genes related to immune function to identify associations with severe infection following treatment of breast cancer with doxorubicin and cyclophosphamide. CD95 mediates the extrinsic apoptosis pathway in haematopoietic cells and a CD95 promoter SNP (rs2234767) has been shown to result in reduced expression of the receptor. MBL2 activates the classical complement pathway in the presence of pathogens and independently of antibodies. Numerous SNPs have been described including a promoter SNP (rs7096206) which results in decreased expression of the protein. Homozygotes for the CD95 minor allele were more likely to experience a grade 3 infection than heterozygote and homozygote wild-type patients (29%, 3% and 5%, respectively p=0.048). CD95 minor allele homozygotes also had higher basal white blood cell and neutrophil counts compared with wild-type allele carriers, which was sustained throughout therapy. There was an allele-dose association between the MBL2 SNP and grade 3 infection, with 2, 8 and 17% of wild-type homozygotes, heterozygotes and minor allele homozygotes, respectively, experiencing grade 3 infection (p=0.02). These associations demonstrate the utility of a pharmacogenetic approach to identify individuals more likely to acquire a life-threatening infection during chemotherapy. The apparent association with a CD95 SNP and a mild neutrophilia merits further investigation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jamieson D, Sunter N, Muro S, et al. Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. Eur J Cancer. 2016. PMID: 27940354. doi:10.1016/j.ejca.2016.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。